Form 4: Centessa Pharmaceuticals Executive Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals, sold 11,494 ordinary shares at an average price of $15.2488 per share on February 25, 2025, under a pre-arranged trading plan.
Summary
- Gregory M. Weinhoff, the Chief Business Officer of Centessa Pharmaceuticals plc, reported a transaction involving the sale of ordinary shares.
- On February 25, 2025, Weinhoff sold 11,494 ordinary shares at a weighted average price of $15.2488.
- The sales were executed under a Rule 10b5-1 trading plan adopted on May 22, 2024.
- Following the transaction, Weinhoff beneficially owns 134,021 ordinary shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a share sale by an executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
Sales by company executives are a normal part of corporate governance. The use of a 10b5-1 trading plan allows insiders to sell shares without being accused of acting on inside information.
Stakeholder Impact
- The sale of shares by an executive could be perceived neutrally or slightly negatively by shareholders, depending on the context and the size of the sale.
Key Dates
| Date | Description |
|---|---|
| May 22, 2024 | Date the Reporting Person adopted the Rule 10b5-1 trading plan |
| February 25, 2025 | Date of the share sale transaction |
| February 26, 2025 | Date of the report |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.